Department of Biochemistry & Molecular Biology, Anhui Medical University, Heifei, Anhui, China.
PLoS One. 2013 Apr 8;8(4):e60701. doi: 10.1371/journal.pone.0060701. Print 2013.
Bioactive peptides, either derived from nature resources or synthesized by rational design, have been demonstrated potential for therapeutic agents against numerous human diseases, including cancer. However, the mechanism of therapeutic peptides against cancer has not been well elucidated. Here we show that PGPIPN, a hexapeptide derived from bovine β-casein, inhibited the proliferation of human ovarian cancer cells line SKOV(3) as well as the primary ovarian cancer cells in vitro. Consistently, PGPIPIN also decreased tumor growth rate in xenograft ovarian cancer model mice in a dose-dependent manner. Further study demonstrated that the anti-tumor effect of PGPIPN is partially through promoting cell apoptosis by inhibiting BCL2 pathway. Thus, our study suggests that PGPIPN is a potential therapeutic agent for the treatment of ovarian cancer or other types of cancer.
生物活性肽，无论是源自天然资源还是通过合理设计合成的，都已被证明具有针对多种人类疾病（包括癌症）的治疗药物的潜力。然而，治疗性肽对癌症的作用机制尚未得到充分阐明。在这里，我们发现 PGPIPN，一种源自牛β-酪蛋白的六肽，可抑制人卵巢癌细胞系 SKOV(3)以及体外原代卵巢癌细胞的增殖。一致地，PGPIPN 也以剂量依赖的方式降低异种移植卵巢癌模型小鼠中的肿瘤生长速度。进一步的研究表明，PGPIPN 的抗肿瘤作用部分是通过抑制 BCL2 通路促进细胞凋亡来实现的。因此，我们的研究表明 PGPIPN 是治疗卵巢癌或其他类型癌症的潜在治疗剂。
